Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
8511984334!ADENOVIRUS TYPE 4 A is a federal award for Dla Troop Support held by Teva Pharmaceuticals Usa, Inc. Estimated value $4M ($4M obligated). Current period of performance ends Mar 25, 2026. Place of performance: PARSIPPANY NJ.
Recompete timing
PublicCurrent PoP ended Mar 25, 2026 (149 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2DP26F3586?
SPE2DP26F3586 (8511984334!adenovirus TYPE 4 a) is a Dla Troop Support award with a potential value of $4M, currently held by Teva Pharmaceuticals Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is SPE2DP-26-F-3586?
SPE2DP-26-F-3586 is the dashed form of PIID SPE2DP26F3586 (8511984334!adenovirus TYPE 4 a), held by Teva Pharmaceuticals Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded SPE2DP26F3586?
Dla Troop Support awarded SPE2DP26F3586 to Teva Pharmaceuticals Usa, Inc (potential $4M).
Who is the incumbent on SPE2DP26F3586?
Teva Pharmaceuticals Usa, Inc is the incumbent. The current period of performance ends Mar 25, 2026.
When does Teva Pharmaceuticals Usa, Inc’s SPE2DP26F3586 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 25, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.